NuvOx Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role. Our product candidate is NanO2, the API of which is dodecafluoropentane. NanO2™ is administered intravenously as an emulsified liquid, containing nano-sized droplets that after entering the body, due to the human body temperature, convert to a gas, which enables them to deliver more oxygen than when in the liquid state. Due to the fact that the size of the NanO2 particle is approximately 30 times smaller in diameter than a red blood cell, the NanO2 particle can partition into tissue, deliver oxygen and further facilitate oxygen transfer from red blood cell to tissue.

S-1/A · 2026-09-16 · 0001213900-26-100586

Company description from the cited filing.